BayesDel generic Pejaver evidence thresholds in ENIGMA comparison
Generic BP4 supporting threshold ≤−0.18 and PP3 supporting threshold ≥0.13, applied to BRCA functional benign reference sets. These are evidence codes, not full pathogenicity classifications.
2 evaluations · 4 results6 open disagreements between studies involve its model
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
Model Capabilities & Hardware Requirements
Deployment facts recorded for BayesDel generic Pejaver evidence thresholds in ENIGMA comparison. Fields the record does not carry are marked not recorded.
Evaluations and results
2 evaluations · 4 results. Different protocols are not a single leaderboard.
Sorted by Proportion (benign reference variants assigned BP4) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.
| Tested configuration | Protocol and dataset | Proportion (benign reference variants assigned BP4) | Proportion (benign reference variants assigned PP3) |
|---|---|---|---|
| BayesDel generic Pejaver evidence thresholds in ENIGMA comparisonEvaluation | BRCA1 generic BayesDel threshold evidence-code assignment, BRCA1 functional reference calibration set | <10% | 29% (best in column) |
| BayesDel generic Pejaver evidence thresholds in ENIGMA comparisonEvaluation | BRCA2 generic BayesDel threshold evidence-code assignment, BRCA2 functional reference calibration set | <10% | 36% |
All 4 result rows with coverage, uncertainty and sources
Filter evaluations
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: BayesDel generic Pejaver evidence thresholds in ENIGMA comparison | Protocol: BRCA1 generic BayesDel threshold evidence-code assignment Dataset: BRCA1 functional reference calibration set | <10% Proportion (benign reference variants assigned BP4) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceBRCA1 generic BayesDel threshold comparator Not reported Aggregation: Not reported Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel · Results, BayesDel calibration, BP4 code would be assigned to <10% of BRCA1 and BRCA2 benign reference variants |
| Configuration: BayesDel generic Pejaver evidence thresholds in ENIGMA comparison | Protocol: BRCA1 generic BayesDel threshold evidence-code assignment Dataset: BRCA1 functional reference calibration set | 29% Proportion (benign reference variants assigned PP3) percent · lower Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceBRCA1 generic BayesDel threshold comparator Not reported Aggregation: Not reported Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel · Results, BayesDel calibration, sentence 29% for BRCA1 and 36% for BRCA2 incorrectly assigned PP3 |
| Configuration: BayesDel generic Pejaver evidence thresholds in ENIGMA comparison | Protocol: BRCA2 generic BayesDel threshold evidence-code assignment Dataset: BRCA2 functional reference calibration set | <10% Proportion (benign reference variants assigned BP4) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceBRCA2 generic BayesDel threshold comparator Not reported Aggregation: Not reported Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel · Results, BayesDel calibration, BP4 code would be assigned to <10% of BRCA1 and BRCA2 benign reference variants |
| Configuration: BayesDel generic Pejaver evidence thresholds in ENIGMA comparison | Protocol: BRCA2 generic BayesDel threshold evidence-code assignment Dataset: BRCA2 functional reference calibration set | 36% Proportion (benign reference variants assigned PP3) percent · lower Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceBRCA2 generic BayesDel threshold comparator Not reported Aggregation: Not reported Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel · Results, BayesDel calibration, sentence 29% for BRCA1 and 36% for BRCA2 incorrectly assigned PP3 |
Source checking is not independent reproduction. Release 2026-11-21-adc15377fab2.
Use this configuration
How it works, versions and access
Related profile: BayesDel. This page retains the exact record and its evaluation context.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
3 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
Facets: method types1 values
| ACMG/AMP interpretation of BRCA1 missense variants: Structure-informed scores add evidence strength granularity to the PP3/BP4 computational evidence Matches the other 7 BayesDel configurations; Ramadane 2025 calls BayesDel a meta-predictor Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: American Journal of Human Genetics 112(5):993, published 2025; PMC12120176 full-text XML | conflicting claim ["source-hash-verification","automated-source-review"] · 2026-10-12 Audit detailsCorrect the method type from none to supervised_machine_learning (use-case baseline review 2026-10-12, table 2). Evidence from docs/reviews/use-cases/baselines-2026-10-12.md. Independent review 2026-10-12: approved. See docs/reviews/2026-10-12-method-type-corrections.md. Conflicting source claim: Field: Claim: metadata-correction-tags-20261012-8aa780483a6028222493 Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Extraction artifact SHA-256: |
Facets: method types1 values
| Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel Matches the other 7 BayesDel configurations; Ramadane 2025 calls BayesDel a meta-predictor Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: 2024 final article; reported VCEP specifications v1.0 | conflicting claim ["source-hash-verification","automated-source-review"] · 2026-10-12 Audit detailsCorrect the method type from none to supervised_machine_learning (use-case baseline review 2026-10-12, table 2). Evidence from docs/reviews/use-cases/baselines-2026-10-12.md. Independent review 2026-10-12: approved. See docs/reviews/2026-10-12-method-type-corrections.md. Conflicting source claim: Field: Claim: metadata-correction-tags-20261012-8aa780483a6028222493 Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Extraction artifact SHA-256: |
| Relationship: configuration of uc-clinical-20260930-method-bayesdel Individual claims | Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel Results; Table 2; reference 22 Version: 2024 final article; reported VCEP specifications v1.0 | source checked ["automated-source-review"] · 2026-09-30 Audit detailsTranscription from inspected primary source. No execution, independent replication or human scientific review. Field: Claim: uc-clinical-20260930-association-bayesdel-pejaver-generic Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Sources and history
Release 2026-11-21-adc15377fab2 · Record review: source checked
1 source record and release history
- Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel · Original source · 2024 final article; reported VCEP specifications v1.0
Technical metadata and record identifiers
Technical metadata for this record is tracked under stable ID uc-clinical-20260930-bayesdel-pejaver-generic.
Related records
- configuration of: BayesDel
- subject: BayesDel generic Pejaver evidence thresholds in ENIGMA comparison: facets.method_types
- subject: Configuration identity: BayesDel generic Pejaver evidence thresholds in ENIGMA comparison
- implemented by: Generic BayesDel computational-evidence threshold baseline
- system: BRCA1 generic BayesDel threshold comparator
- system: BRCA2 generic BayesDel threshold comparator
How to cite
BayesDel generic Pejaver evidence thresholds in ENIGMA comparison. Rewire biological model benchmark database, release 2026-11-21-adc15377fab2. https://benchmarks.rewirebio.io/database/configuration/uc-clinical-20260930-bayesdel-pejaver-generic/
Release 2026-11-21-adc15377fab2. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.
The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence